EXTON, Pa.--(BUSINESS WIRE)--Frontage, a full service contract research organization (CRO), today announced the appointment of Michael S. Willett, PharmD., RAC as President of its clinical business unit.
Dr. Willett is a seasoned industry professional with more than 25 years of experience in clinical research involving new chemical entities, biologics, biosimilars, medicines targeted for new therapeutic uses (505(b)(2) programs), consumer health, and generic drugs. In 1994, Dr. Willett established Advanced Biomedical Research, Inc. (ABR), a Phase I-II clinical CRO which was later acquired by Frontage in 2008.
Help employers find you! Check out all the jobs and post your resume.
Dr. Willett is a seasoned industry professional with more than 25 years of experience in clinical research involving new chemical entities, biologics, biosimilars, medicines targeted for new therapeutic uses (505(b)(2) programs), consumer health, and generic drugs. In 1994, Dr. Willett established Advanced Biomedical Research, Inc. (ABR), a Phase I-II clinical CRO which was later acquired by Frontage in 2008.
Help employers find you! Check out all the jobs and post your resume.
